|
Apath is
a privately held technology licensing company with a
focus on hepatitis C virus (HCV) and other human viral pathogens. Apath applies state-of-the
art molecular virology and viral genetics in order to assist clients
in the discovery and
development of novel therapeutic products for the treatment of viral
infections. Apath’s primary focus is on RNA viruses. Most
medically important viruses are RNA viruses including hepatitis C
virus, influenza virus, respiratory syncytial virus (RSV), and
hemorrhagic fever viruses.
Apath's founder and key employees
have a proven track record and comprehensive expertise in virology
and molecular biology. Apath has key patents, proprietary know-how,
and license agreements related to hepatitis C virus (HCV) and other
important human viral pathogens. In addition, Apath has state
of the art discovery tools developed for HTS antiviral screening platforms.
|
